906649-94-3 Usage
General Description
2,6-dibromo-4-fluorotoluene is a chemical compound with the molecular formula C7H5Br2F. It is a colorless liquid with a faint odor and is insoluble in water. 2,6-dibromo-4-fluorotoluene is primarily used as an intermediate in the production of pharmaceuticals and agrochemicals. It is also used as a building block in the synthesis of various organic compounds and materials. 2,6-dibromo-4-fluorotoluene is a halogenated aromatic compound, and its bromine and fluorine substituents make it a valuable reagent for organic synthesis and chemical research. It is important to handle this compound with caution, as it may cause irritation to the skin, eyes, and respiratory system upon exposure.
Check Digit Verification of cas no
The CAS Registry Mumber 906649-94-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,0,6,6,4 and 9 respectively; the second part has 2 digits, 9 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 906649-94:
(8*9)+(7*0)+(6*6)+(5*6)+(4*4)+(3*9)+(2*9)+(1*4)=203
203 % 10 = 3
So 906649-94-3 is a valid CAS Registry Number.
906649-94-3Relevant articles and documents
Discovery of disubstituted phenanthrene imidazoles as potent, selective and orally active mPGES-1 inhibitors
Giroux, Andre,Boulet, Louise,Brideau, Christine,Chau, Anh,Claveau, David,Cote, Bernard,Ethier, Diane,Frenette, Richard,Gagnon, Marc,Guay, Jocelyne,Guiral, Sebastien,Mancini, Joseph,Martins, Evelyn,Masse, Frederic,Methot, Nathalie,Riendeau, Denis,Rubin, Joel,Xu, Daigen,Yu, Hongping,Ducharme, Yves,Friesen, Richard W.
body text, p. 5837 - 5841 (2010/04/28)
Phenanthrene imidazoles 26 and 44 have been identified as novel potent, selective and orally active mPGES-1 inhibitors. These inhibitors are significantly more potent than the previously reported chlorophenanthrene imidazole 1 (MF63) with a human whole blood IC50 of 0.20 and 0.14 μM, respectively. It exhibited a significant analgesic effect in a guinea pig hyperalgesia model at oral doses as low as 14 mg/kg. Both active and selective mPGES-1 inhibitors (26 and 44) have a relatively distinct pharmacokinetic profile and are suitable for clinical development. Crown Copyright
